MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
0.7947
+0.0807
+11.30%
After Hours: 0.8200 +0.0253 +3.18% 19:51 02/10 EST
OPEN
0.7194
PREV CLOSE
0.7140
HIGH
0.8500
LOW
0.7160
VOLUME
5.39M
TURNOVER
--
52 WEEK HIGH
1.390
52 WEEK LOW
0.5062
MARKET CAP
95.59M
P/E (TTM)
-0.9504
1D
5D
1M
3M
1Y
5Y
1D
Top Analysts Just Picked These 3 ‘Strong Buy’ Stocks, 2/10/26
TipRanks · 14h ago
2 ‘Strong Buy’ Stocks to Buy Today, 2/9/2026, According to Top Analysts
TipRanks · 1d ago
Immunic (IMUX) Receives a Buy from William Blair
TipRanks · 1d ago
Immunic Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $8 Price Target
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Hims & Hers Health (HIMS)
TipRanks · 1d ago
Weekly Report: what happened at IMUX last week (0202-0206)?
Weekly Report · 1d ago
Immunic Announced The Presentation Of Additional Data From Its Phase 2 CALLIPER Trial Of Lead Asset, Vidofludimus Calcium (IMU-838), For Progressive Multiple Sclerosis At The Americas Committee For Treatment And Research In Multiple Sclerosis Forum 2026
Benzinga · 6d ago
More
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.